期刊文献+

胰腺癌的放射免疫治疗进展 被引量:1

Radioimmunotherapy of pancreatic cancer
下载PDF
导出
摘要 胰腺癌是常见的肿瘤,但预后很差,传统治疗的结果令人失望,放射免疫治疗提供了一个新的治疗途径。单克隆抗体具有高度的特异性,放射性核素在肿瘤部位积聚高而达到杀伤瘤细胞的目的。完整的单抗因其分子质量较大而难于达到肿瘤内部,且易诱发人抗鼠抗体反应。基因工程抗体因具有更高的亲和力和更容易进入肿瘤内部,已成为放射免疫治疗的热点及突破胰腺癌临床治疗的关键所在,将在胰腺癌的治疗中发挥重要作用。 Pancreatic cancer is a comman disease that is seldom cured.Coventional therapy remaining dismal,immuno-radiotherapy may provide an immproved alternative for the treatment of pancreatic cancer.Because monoclonal antibody has a high specificity,radionuclide can retain enough high concentrations in tumor areas to kill tumor cells.But intact monoclonal antibody,due to their large size,shows poor defusion from the vasculature into and through the tumor,and it always induces a human anti-mouce.Geneticengineering antibody has led to a significant amount of research in radioim-munotherapy.It is essential to make improved progress for the treatment of pancreatic cancer.
出处 《国外医学(放射医学核医学分册)》 2003年第4期154-156,共3页 Foreign Medical Sciences(Section of Radiation Medicine and Nuclear Medicine)
关键词 胰腺癌 放射免疫治疗 单克隆抗体 放射性核素治疗 诊断 治疗 pancreatic cancer radioimmunotherapy monoclonal antibody geneticengineering antibody
  • 相关文献

参考文献11

  • 1David VG, Thomas C, David M, et al. Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4[J]. CRC Crit Rev Oncol Hematol, 2001, 39: 147-154.
  • 2Sakorafas GH, Tsiotou AG, Tsiotos GG. Molexular biology of pancreatic cancer, oncogenes, tumour suppressor genes,growth factors, and their receptors from a clinical perspective[J]. Cancer Trentment Rev, 2000, 26: 29-52.
  • 3Goldenberg J, Hans J, SerengulamV, et al. Advance in the use of monoclonal antibodies in cancer radiotherapy [J].Pharm Sci Tech Today, 2000, 3: 90-98.
  • 4Sawada T, Nishihara T, Yamamoto A, et al. Preoperative clinical radioimmunodetection of pancreatic cancer by 111Inlabeledchimeric monoclonal antibody Nd2 [J]. Jpn J Cancer Res, 1999, 90:1179-1186.
  • 5Nishihara T, Sawada T, YamamotoA, et al. Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibobody Nd2 and exprrimental immunotherapy for pancreatic cancer[J]. Jpn J Cancer Res, 2000, 91(8): 817-824.
  • 6Pavlinkova G, Beresford GW, Booth B J, et al. Pharmacokinetics and biodistribution of engi-neered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts[J]. J Nucl Med, 1999, 40: 1536-1546.
  • 7Colcher D, Goel A, Pavlinkova G, et al. Effects of genetic engineeringon the pharmacokinetics of antibodies [J]. Q J Nucl Med, 1999, 43: 132-139.
  • 8Pavlinkova G, Booth BJ, Batra SK, ct al. Radioimmunotherapy of human colon cancer xenografts using a dimeric singlechain Fv antibody construct[J]. Clin Cancer Rcs, 1999,5: 2613-2619.
  • 9Flynn AA, Pedleg RB, Green A J, et al. Antibody and radionuclide characteristics and the enhancement of the effectuveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour [J]. Int J Radiat Biol.2002, 78(5): 407-415.
  • 10Cardillo TM, Blumenthal R, Ying Z, et al. Combined gemcitabine and radioimunotherapy-forthe treament of pancreatic cancer[J]. Int J Cancer, 2002, 97(3): 386-392.

同被引文献24

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部